ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0516

Management of Elederly Patients with Rheumatoid Arthritis Treated with Tocilizumab : Comparison of Patients over and Under 75 Years Old

Bruno Fautrel1, Alain SARAUX2, Isabelle Idier3, Henri Bonnabau4, Geoffray Bizouard5 and BERNARD COMBE6, 1INSERM, UMRS 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Sorbonne University – Assistance Publique-Hôpitaux de Paris, Département de Rhumatologie, Hôpital Pitié-Salpêtrière, Paris, Ile-de-France, France, 2CHU Brest, Brest, France, 3Chugai Pharma france, Puteaux, Ile-de-France, France, 4IQVIA France, Bordeaux, France, 5IQVIA France, La Defense, Ile-de-France, France, 6Montpellier University, LA GRANDE MOTTE, Languedoc-Roussillon, France

Meeting: ACR Convergence 2024

Keywords: Cohort Study, Disease-Modifying Antirheumatic Drugs (Dmards), rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: RA – Treatment Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Few real-life long-term data are available in RA patients initiating tocilizumab (TCZ) depending on age. The objective of this study was to compare the characteristics and management of patients over or under 75 years of age (geriatric age, with no data in RCT).

Methods: Patients having initiated TCZ (IV or SC) with a RA diagnosis in the SNDS (French national health-insurance database, 67 million of people) with 1st date of delivery of TCZ between Jan. 2015 and Dec. 2016 (index date) were included. The end of follow-up date was the study end date (Dec. 2019), the date of death or the date of last reimbursement in the database. Medical history and comorbidities in the 4 years before the index date are reported. A therapeutic line was defined by maintained DMARD deliveries without change such as prolonged ( >90 days) or permanent cessation, switch to another MoA or addition of csDMARD. For tolerance the comparison was made using an adjusted Cox proportional-hazard model with time dependent variables to consider the change of lines of treatments (1st event is considered). aHRs (95% CI) use < 75 years old as reference.

Results: 4290 patients treated with TCZ were included, among them 402 were ≥75 years old (77.6% women). For those ≥75 years old, TCZ was administered SC in 48.5% of the patients, without csDMARD in 66.2% (< 75 years: 58.1% and 51.2% respectively). 83.3% of the patients were on steroids (< 75 years: 76.1%). 69.9% of ≥75 years old had previously received any DMARD (<75 years: 83.6%). Medical history and comorbidities are detailed in the table. 

In ≥75 years old, therapeutic maintenance of TCZ was 54%, 39%, 32%, and 23 % at 1, 2, 3 and 4 years. It was 57%, 43%, 34% and 26% among < 75 years old patients respectively (Fig.). The median duration of TCZ was 15 months 95%CI (11.6-18.6) in patients ≥75 years old and 18 months 95%CI (16.6-19.5) in < 75 years old. 

55.5% of ≥75 years old and 20.4% of < 75 years old had received an influenza vaccine within the year. 42% of ≥75 years old and 53.9% of < 75 years old received an anti-pneumococcal vaccine within 4 years before index date. At 5 years, patients ≥75 years old had had 188 episodes of severe infections [47.6% of patients, aHR:1.80 (1.53-2.13)], 73 acute CV events [18.1%, aHR 2.13 (1.60-2.83)], 41 digestive perforations [10.1%, aHR 1.32 (0.92-1.88)], 27 hematological events [6.7%, aHR 1.89 (1.22-2.91)] and 17 cancers [4.2%, aHR 1.06 (0.62-1.79)]. 161 patients died, including 67 of the ≥75 years old.

Conclusion: This analysis shows that TCZ can be a relevant option in older RA patients with therapeutic maintenance close to that of younger patients. However, patient monitoring should be carefully followed-up since these patients are more likely to develop adverse events.

Supporting image 1

Supporting image 2


Disclosures: B. Fautrel: AbbVie, 2, 5, Amgen, 2, Biogen, 2, BMS, 2, Celgene, 2, Celltrion, 2, Chugai, 2, Fresenius Kabi, 2, Galapagos, 2, Janssen, 2, Lilly, 2, 5, Medac, 2, MSD, 2, 5, Mylan, 2, Nordic Pharma, 2, Novartis, 2, Pfizer, 2, 5, Roche, 2, Sandoz, 2, Sanofi-Genzyme, 2, Sobi, 2, UCB, 2; A. SARAUX: Abbvie, BMS, Galapagos, Lilly, Novartis, Nordic, Pfizer, Roche-Chugai, Sanofi, UCB, 6, Abbvie, Bms, Lilly, Novartis, 5; I. Idier: Chugai Pharma France, 3; H. Bonnabau: Chugai Pharma France, 7; G. Bizouard: Chugai Pharma France, 7; B. COMBE: AbbVie/Abbott, 2, Celltrion, 2, Chugai Pharma France, 2, Eli Lilly, 2, Nordic, 2, Pfizer, 2.

To cite this abstract in AMA style:

Fautrel B, SARAUX A, Idier I, Bonnabau H, Bizouard G, COMBE B. Management of Elederly Patients with Rheumatoid Arthritis Treated with Tocilizumab : Comparison of Patients over and Under 75 Years Old [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/management-of-elederly-patients-with-rheumatoid-arthritis-treated-with-tocilizumab-comparison-of-patients-over-and-under-75-years-old/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/management-of-elederly-patients-with-rheumatoid-arthritis-treated-with-tocilizumab-comparison-of-patients-over-and-under-75-years-old/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology